AGTC Email Formats

Biotechnology Research • Alachua, Florida, United States • 101-200 Employees

AGTC Email Formats

AGTC uses 3 email formats. The most common is {first name}{last name} (e.g., johndoe@agtc.com), used 50% of the time.

Format	Example	Percentage
{first name}{last name}	johndoe@agtc.com	50%
{last name}{last name}	doedoe@agtc.com	33.3%
{first initial}{last name}	jdoe@agtc.com	16.7%

Key Contacts at AGTC

Susan Sleep

Director, Assay Development

John Grady

Associate Director, Downstream Process Development

Anna Jennings

Owner

Accounting And Gst Training Center

Founder

Shahinaz Arabia

Executive Director

Yehuda Ayalon

Ceo

Company overview

Headquarters	14193 NW 119th Terrace, Suite #10, Alachua, Florida 32615, US
Phone number	+13864622204
Websites	agtc.com beacontx.com
NAICS	541714
SIC	873
Founded	1999
Employees	101-200
Socials

About AGTC

AGTC is a clinical-stage biotechnology company that uses its proprietary gene therapy platform to develop products designed to transform the lives of patients with severe diseases, with an initial focus in ophthalmology. AGTC's lead product candidates are designed to treat inherited orphan diseases of the eye, caused by mutations in single genes that significantly affect visual function and currently lack effective medical treatments. AGTC's product pipeline includes six named ophthalmology development programs across five targets (X-linked retinoschisis (XLRS), X-linked retinitis pigmentosa (XLRP), achromatopsia, wet age-related macular degeneration and blue cone monochromacy), two non-ophthalmology programs (alpha-1 antitrypsin deficiency and adrenoleukodystrophy) and AGTC is continuing to develop early research studies in additional indications. The company is also exploring genetic defects in cells in the inner ear that lead to deafness and expects to advance several product candidates into development within the next few years. AGTC employs a highly targeted approach to selecting and designing its product candidates, choosing to develop therapies for indications having high unmet medical need, clinical feasibility and commercial potential. AGTC has a significant intellectual property portfolio and extensive expertise in the design of gene therapy products including capsids, promoters and expression cassettes, as well as, expertise in the formulation, manufacture and physical delivery of gene therapy products Find AGTC on YouTube at goo.gl/sMdJqX.